据知情人士透露，私募股权公司博裕资本（Boyu Capital）正在考虑出售医疗器械制造商Quasar Medical。
Buyout firm Boyu Capital is considering a sale of medical device maker Quasar Medical, according to people familiar with the matter.
这些人士称，博裕正就剥离这家总部位于新加坡的Quasar与潜在顾问进行初步讨论，该交易估值可能超过10亿美元。这些人士要求匿名，因为他们正在讨论机密信息。
Boyu is in early discussions with potential advisers about a divestment of Singapore-based Quasar, which could be worth more than $1 billion in a deal, the people said, asking not to be identified discussing confidential information.
Quasar成立于1988年，是一家服务于医疗器械行业的合同研发生产组织（CDMO）。
Established in 1988, Quasar is a contract development and manufacturing organization, or CDMO, serving the medical device industry.
根据新闻稿，它为包括强生（Johnson & Johnson）、美敦力（Medtronic Plc）、雅培（Abbott Laboratories）和波士顿科学（Boston Scientific Corp.）在内的客户提供外包设计、开发和生产服务。其网站显示，该公司在全球拥有11个设施和约5000名员工。
It provides outsourced design, development and production services for customers that have included Johnson & Johnson, Medtronic Plc, Abbott Laboratories and Boston Scientific Corp., according to a press release. The company has 11 facilities and about 5,000 employees globally, its website shows.
这些人士称，目前的讨论仍处于初步阶段，可能不会导致交易达成。博裕和Quasar的代表未立即回应置评请求。
Deliberations are preliminary and may not result in a transaction, the people said. Representatives for Boyu and Quasar didn’t immediately respond to requests for comment.
博裕于2023年同意从Longreach Group和创始人家族少数股东手中收购Quasar。
Boyu agreed to buy Quasar from Longreach Group and founder family minority shareholders in 2023.
彭博新闻当时报道称，该交易对Quasar的估值超过6亿美元。
The deal valued Quasar at more than $600 million, Bloomberg News reported at the time.